Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554691 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL27182137 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL11264960 | 0.86 | HPGD (0.54) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL4072060 | 0.84 | SLC18A3 (0.64) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| Hydrochloric Acid SCHEMBL4068642 | 0.83 | SLC18A3 (0.62) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL17460207 | 0.82 | SLC18A3 (0.66) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL21121132 | 0.78 | HPGD (0.65) | SMN1; SMN2HPGDKMT2ASLC18A3CYP2D6 | |
| SCHEMBL6621057 | 0.77 | SMN1; SMN2 (0.97) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL6621926 | 0.77 | SMN1; SMN2 (0.97) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B | |
| SCHEMBL6621053 | 0.77 | SMN1; SMN2 (0.97) | SMN1; SMN2HPGDKMT2ASLC18A3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | SMN1; SMN2 4811/4885HPGD 2624/4885KMT2A 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.